D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. (Q38965039)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 April 2015

Language	Label	Description	Also known as
English	D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.	scientific article published on 28 April 2015

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

0 references

0 references

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Cheryl Corcoran

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Joshua T Kantrowitz

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Scott W Woods

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Barbara Cornblatt

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Huaihou Chen

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Gail Silipo

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Daniel C Javitt

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

28 April 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

The Lancet Psychiatry

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

403-412

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Negative symptoms in individuals at clinical high risk of psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

NMDA receptor and schizophrenia: a brief history

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Translating glutamate: from pathophysiology to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

D-alanine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose D-serine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycine treatment of the risk syndrome for psychosis: report of two pilot studies

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating the Dimension of a Model

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bayesian measures of model complexity and fit

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of adjunctive bitopertin (5 and 10mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the phase III DayLyte study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the Phase III FlashLyte Study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2815%2900098-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2215-0366(15)00098-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

release_tpvua2pmzrebzbbvbhpojuk27a

1 reference

https://api.fatcat.wiki/v0/release/tpvua2pmzrebzbbvbhpojuk27a

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26360284%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38965039&oldid=1836948525"